CN109965072A - 一种养护肝脏的压片糖果及其制备方法与应用 - Google Patents
一种养护肝脏的压片糖果及其制备方法与应用 Download PDFInfo
- Publication number
- CN109965072A CN109965072A CN201910276758.0A CN201910276758A CN109965072A CN 109965072 A CN109965072 A CN 109965072A CN 201910276758 A CN201910276758 A CN 201910276758A CN 109965072 A CN109965072 A CN 109965072A
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- pressed candy
- vitamin
- trehalose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 75
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 50
- 239000000843 powder Substances 0.000 claims abstract description 50
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 44
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 33
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 33
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 26
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 25
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 25
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 25
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 25
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 25
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 25
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 25
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 25
- 235000021014 blueberries Nutrition 0.000 claims abstract description 25
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 25
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 25
- 239000011718 vitamin C Substances 0.000 claims abstract description 25
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 24
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 24
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 24
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 24
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 24
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 24
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 24
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 24
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 24
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 22
- 239000000126 substance Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000011122 softwood Substances 0.000 claims description 15
- 238000007605 air drying Methods 0.000 claims description 10
- 238000012423 maintenance Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 235000020985 whole grains Nutrition 0.000 claims description 8
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000007779 soft material Substances 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 abstract description 12
- 108090000340 Transaminases Proteins 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 230000008929 regeneration Effects 0.000 abstract description 7
- 238000011069 regeneration method Methods 0.000 abstract description 7
- 238000001784 detoxification Methods 0.000 abstract description 5
- 230000010224 hepatic metabolism Effects 0.000 abstract description 4
- 210000000232 gallbladder Anatomy 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 102000003929 Transaminases Human genes 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 210000003494 hepatocyte Anatomy 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 35
- 230000000694 effects Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 206010019837 Hepatocellular injury Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 231100000437 hepatocellular injury Toxicity 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 8
- 230000003908 liver function Effects 0.000 description 7
- 102000014898 transaminase activity proteins Human genes 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108050006747 Hepatic lipases Proteins 0.000 description 5
- 102000019267 Hepatic lipases Human genes 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004987 nonapoptotic effect Effects 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 210000004738 parenchymal cell Anatomy 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 229930014669 anthocyanidin Natural products 0.000 description 3
- 150000001453 anthocyanidins Chemical class 0.000 description 3
- 235000008758 anthocyanidins Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 244000080767 Areca catechu Species 0.000 description 2
- 235000006226 Areca catechu Nutrition 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 101000941292 Mus musculus Hepatic triacylglycerol lipase Proteins 0.000 description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229920002414 procyanidin Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000001822 Ilex glabra Species 0.000 description 1
- 235000001932 Ilex glabra Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 241001442514 Schistosomatidae Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种养护肝脏的压片糖果及其制备方法与应用,压片糖果,包括如下重量份数的物质:海藻糖20~90份,葡萄籽提取物1~40份,蓝莓粉1~8份,枸杞粉1~8份,维生素C 1~10份,甘草酸铵1~8份,微晶纤维素1~50份,表没食子儿茶素没食子酸酯0.1~5份,硬脂酸镁0.1~5份;还提供了其制备方法与应用。本发明的有益效果是:搭配合理,短效与长效结合,可促进肝细胞再生,改善受损害肝细胞再生功能,降低转氨酶,降低肝脏脂肪,促进肝脏代谢,增强肝胆解毒功能;其制备方法简单、生产工艺流程少、成本较低、食用方便,具有较高的实用性,利于规模化生产。
Description
技术领域
本发明涉及食品技术领域,具体涉及一种养护肝脏的压片糖果及其制备方法与应用。
背景技术
肝脏是人体最大的以代谢功能为主的内脏器官,肝脏可将体内的毒素分解及代谢出体外,因此肝脏的健康直接关系到人体的健康状况。病原体感染、大量食用高油高脂高糖分食物、劳累、服用药物以及吸烟、饮酒等均会对肝脏健康造成损伤,导致脂肪肝、肝炎、肝纤维化甚至肝癌等疾病,因此对肝脏的养护十分重要。
目前我国男性人群中患脂肪肝人数可超过5%。患者会出现某些类似慢性肝炎的体征,如肝功异常、肝区不适等,此种情况被为脂肪性肝炎,脂肪肝代谢异常往往还能加速和加重冠心病、高血压、糖尿病、胆石症的发生或恶化,中度以上脂肪肝会随着病情发现转化为肝纤维化,肝纤维化是各种损伤因子累及肝脏后的一种病理状态。任何能造成肝脏损害的因素均可致肝脏发生纤维化,如病毒性肝炎、脂肪性肝炎(包括酒精性或非酒精性)、自身免疫性肝病、血吸虫肝病、药物性肝病和一些先天代谢性疾病等均可引起肝纤维化。肝纤维化过程中肝实质细胞数量减少,肝小叶结构改变,肝脏代谢功能紊乱,致肝脏功能逐渐丧失,最终发展为肝硬化直至肝癌。
饮食不规律,饮酒、加班熬夜等不良生活习惯,导致肝脏问题的人数越来越多。典型的肝脏问题如下:1、肝功能受损的人消化功能差,因此会有食欲不振、食后胀满、恶心、呕吐、腹泻、腹痛、厌油腻或便秘等症状;2、肝胆同源,肝功能不好的人胆色素代谢异常,可致黄疸;眼睛和皮肤黄浊可能是肝实质细胞受损导致的高胆红素引起的黄疸所导致;3、肝细胞受损可致血清转氨酶等酶类增高,而胆碱脂酶降低,表现为乏力、易倦、思睡等;4、肝不好的人也会出现情绪不稳定,易怒或者生闷气,中医认为,肝主疏泄、调畅气机。若是肝气条达,则精神愉悦;若肝气不舒,则情绪抑郁、心智不舒;5、中医亦认为眼睛和肝联系紧密,认为肝藏血,主筋,开窍于目;眼睛会反映出肝脏的一些病变,例如眼睛发红表示肝火旺盛,肝火大还会引起口干舌燥、口苦、口臭、睡眠质量差、易醒、身体闷热等等。
目前,市面上针对肝脏保健方面的产品主要是以奶蓟草、维生素B族、卵磷脂、胆碱等保健食品原料为主,然而,这些保健品往往有效成分较为单一,由于加工工艺原因,进入消化道后人体不能对原料中的有效成分进行充分利用,导致护肝效果不佳;此外,由于大部分此类产品仅具备排出转氨酶效果而忽略了对肝实质细胞的滋养和再生支持,长期服用不仅对肝脏养护效果难以达到宣称效果,甚至会造成其他方面的副作用。
发明内容
本发明的目的是提供养护肝脏的压片糖果,其可促进肝细胞再生,改善受损害肝细胞再生功能,降低转氨酶,降低肝脏脂肪,促进肝脏代谢,增强肝脏解毒功能。
本发明的另一目的是提供一种养护肝脏的压片糖果的制作方法,其方法简单、生产工艺流程少、成本较低、食用方便,具有较高的实用性,利于规模化生产。
本发明的还有一目的是提供了养护肝脏的压片糖果在护肝方面的应用。
本发明的目的是通过这样的技术方案实现的,一种养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖20~90份,葡萄籽提取物1~40份,蓝莓粉1~8份,枸杞粉1~8份,维生素C 1~10份,甘草酸铵1~8份,微晶纤维素1~50份,表没食子儿茶素没食子酸酯0.1~5份,硬脂酸镁0.1~5份。
其中,葡萄籽提取物和蓝莓粉中具有较高含量的原花青素和花青素,具有抗氧化、护肝作用;枸杞粉、维生素C和甘草酸铵等均具有保肝护肝作用。具体地,枸杞粉中主要成分枸杞多糖可降低肝细胞损伤所致血清谷丙转氨酶(ALT)升高,可减轻酒精性肝损伤,且有一定的量效关系;原花青素(PCs)是葡萄籽提取物中所含的主要物质之,其是一类多酚化合物,有较强的抗氧化活性,能拮抗乙醇诱导的肝细胞损害,具有保肝作用;花青素的作用不仅使植物呈现五彩缤纷的颜色,也具有降低酶的活性,抗变异等保健功能的活性分子,研究表明有一定花青素浓度的提取物能有效预防不同阶段癌变发生;甘草酸铵有护肝、抗炎、增强免疫的作用,给予患者甘草酸铵,可有效降低多种转氨酶;维生素C可增强免疫力,减少肝细胞损伤,促进肝细胞代谢,大剂量维生素C可明显改善肝炎症状,降低转氨酶,降低总胆红素,缩短肝炎治愈和恢复时间;表没食子儿茶素没食子酸酯(EGCG)于2010年被原卫生部批准为新资源食品,食用量≤300mg/d,具有抗炎和抗氧化等作用,可有效治疗或缓解肝损伤;海藻糖不仅具有低聚糖的特性,而且还具有独特的生物活性,即它对生物体和生物分子具有独特的非特异性保护作用,此外还有低热值、防龋齿、口感好、不易吸湿等特点,可调节肠道菌群、润肠通便、调节血脂、调节免疫,是理想的食品原料;硬脂酸镁为无味,微溶于水,可溶于热乙醇的粉状物,在本发明中主要用作助流剂,使用于压片的粉料具有良好的流动性和可压性。
由于微晶纤维素分子之间存在氢键,受压时氢键缔合,故具有高度的可压性,常被用作于黏合剂;压制的片剂遇到液体后,水分迅速进入含有微晶纤维素的片剂内部,氢键即刻断裂,所以可作为崩解剂;此外,其还能够提高片剂的硬度。
本发明实施例中海藻糖应符合GB/T 23529的规定;葡萄籽提取物的原花青素含量≥40%,且应符合GB/T 2760的规定;蓝莓粉的花青素含量≥3%,且应符合GB/T 29602的规定;枸杞粉的枸杞多糖含量≥40%,且应符合GB/T 29602的规定;甘草酸铵纯度≥90%,且应符合GB 1886.242的规定;表没食子儿茶素没食子酸酯含量≥90%,应符合卫生部2010年第17号公告的规定;维生素C应符合GB14754的规定;微晶纤维素应符合GB 1886.103的规定;硬脂酸镁应符合GB 1886.91的规定。
本发明中,以葡萄籽提取物为主,辅之以蓝莓粉,两者起到协同作用,起到抗氧化、护肝作用;海藻糖的加入进一步优化了发生作用的环境,枸杞粉、维生素C和甘草酸铵进一步加强了对肝脏的保护作用,表没食子儿茶素没食子酸酯可有效治疗或缓解肝损伤,上述各种物质相互协同,共同起到对肝脏的养护作用,而添加的硬脂酸镁和微晶纤维素则在制作压片糖果时可增加流动性和可压性,起到崩解剂、增加强度的作用。多种物质之间相互结合使用,搭配合理,短效与长效结合,其有益效果在于促进肝细胞再生,改善受损害肝细胞代谢功能,降低转氨酶,降低肝脏脂肪,促进肝脏代谢,增强肝脏解毒功能。
本发明中的另一目的是通过这样的技术方案实现的,一种养护肝脏的压片糖果的制备方法,包括以下步骤:
S1,分别按照比例将葡萄籽提取物、蓝莓粉、枸杞粉、维生素C、甘草酸铵和表没食子儿茶素没食子酸酯过30目筛,并按照配方量混合,然后置于三维混合机中,于10~30r/min转速下混合20~40min;
S2,混匀的物料转入槽式混合机中,加入40%~60%的食用乙醇溶液,混合均匀,制成软材;
S3,将软材转入摇摆制粒机过20~40目筛网,制成初级颗粒;
S4,将初级颗粒鼓风干燥,控制水分<5%;
S5,干燥后的初级颗粒分别过30~50目和50~70目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于10~30r/min转速下预混20~40min;
S7,再将配方量的硬脂酸镁投入三维混合机,于10~30r/min转速下总混10~30min;
S8,总混后的物料置于旋转式高速压片机中进行压片。
上述制作方法步骤中,优选地,S4中初级颗粒于40~60℃鼓风干燥3~6h;S8中片重为0.6~0.8g/片。
本发明中的还有一目的是通过这样的技术方案实现的,养护肝脏的压片糖果的应用,直接食用来养护肝脏。具体地,可以含服、直接吞服或溶化后饮用。
由于采用了上述技术方案,本发明具有如下的优点:搭配合理,短效与长效结合,可促进肝细胞再生,改善受损害肝细胞代谢功能,降低转氨酶,降低肝脏脂肪,促进肝脏代谢,增强肝脏解毒功能;其制备方法简单、生产工艺流程少、成本较低、食用方便,具有较高的实用性,利于规模化生产。
附图说明
图1为本发明中小鼠肝脂肪酶(HL)的测定结果对比示意图;
图2为本发明中小鼠血清AST(谷草转氨酶)的测定结果对比示意图;
图3为本发明中小鼠ALT(谷丙转氨酶)的测定结果对比示意图;
图4为本发明中小鼠LDH(乳酸脱氢酶)的测定结果对比示意图。
其中,A-阴性对照组;B-模型组;C-实施例1样品组;D-实施例2样品组;E-实施例3样品组;F-对比例1样品组;G-对比例2样品组;H-对比例3样品组。
具体实施方式
下面结合附图、实施例和对比例对本发明作进一步的说明。
实施例1
一种养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖40份,葡萄籽提取物5份,蓝莓粉1份,枸杞粉1份,维生素C 2份,甘草酸铵1份,微晶纤维素2份,表没食子儿茶素没食子酸酯0.1份,硬脂酸镁0.1份。
上述配方的制备方法,包括以下步骤:
S1,分别将葡萄籽提取物、蓝莓粉、枸杞粉、维生素C、甘草酸铵、表没食子儿茶素没食子酸酯过30目筛,并按照配方量混合,然后置于三维混合机中,于10r/min转速下混合20min;
S2,混匀的物料转入槽式混合机中,加入40%浓度食用乙醇溶液,混合均匀,制成软材;
S3,上述软材转入摇摆制粒机过20目筛网,制成初级颗粒;
S4,初级颗粒于40℃鼓风干燥3h,控制水分<5%;
S5,干燥后的初级颗粒分别过30目和50目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于10r/min转速下预混20min;
S7,再将配方量的硬脂酸镁投入三维混合机,于10r/min转速下总混10min;
S8,总混后的物料置于旋转式高速压片机中进行压片,片重控制在约0.65g/片。
实施例2
一种养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖57份,葡萄籽提取物12份,蓝莓粉2份,枸杞粉2份,维生素C 3份,甘草酸铵2份,微晶纤维素20份,表没食子儿茶素没食子酸酯1份,硬脂酸镁1份。
上述配方的制备方法,包括以下步骤:
S1,分别将葡萄籽提取物、蓝莓粉、枸杞粉、维生素C、甘草酸铵、表没食子儿茶素没食子酸酯过30目筛,并按照配方量混合,然后置于三维混合机中,于20r/min转速下混合30min;
S2,混匀的物料转入槽式混合机中,加入50%浓度食用乙醇溶液,混合均匀,制成软材;
S3,上述软材转入摇摆制粒机过30目筛网,制成初级颗粒;
S4,初级颗粒于50℃鼓风干燥4h,控制水分<5%;
S5,干燥后的初级颗粒分别过40目和60目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于20r/min转速下预混30min;
S7,再将配方量的硬脂酸镁投入三维混合机,于20r/min转速下总混20min;
S8,总混后的物料置于旋转式高速压片机中进行压片,片重控制在约0.65g/片。
实施例3
一种养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖80份,葡萄籽提取物25份,蓝莓粉5份,枸杞粉5份,维生素C 6份,甘草酸铵5份,微晶纤维素30份,表没食子儿茶素没食子酸酯2份,硬脂酸镁2份。
上述配方的制备方法,包括以下步骤:
S1,分别将葡萄籽提取物、蓝莓粉、枸杞粉、维生素C、甘草酸铵、表没食子儿茶素没食子酸酯过30目筛,并按照配方量混合,然后置于三维混合机中,于30r/min转速下混合40min;
S2,混匀的物料转入槽式混合机中,加入60%浓度食用乙醇溶液,混合均匀,制成软材;
S3,上述软材转入摇摆制粒机过40目筛网,制成初级颗粒;
S4,初级颗粒于60℃鼓风干燥6h,控制水分<5%;
S5,干燥后的初级颗粒分别过50目和70目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于30r/min转速下预混40min;
S7,再将配方量的硬脂酸镁投入三维混合机,于30r/min转速下总混30min;
S8,总混后的物料置于旋转式高速压片机中进行压片,片重控制在约0.65g/片。
对比例1:
一种养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖57份,枸杞粉2份,维生素C 3份,甘草酸铵2份,微晶纤维素20份,表没食子儿茶素没食子酸酯1份,硬脂酸镁1份。
上述配方的制备方法,包括以下步骤:
S1,分别将枸杞粉、维生素C、甘草酸铵、表没食子儿茶素没食子酸酯过30目筛,并按照配方量混合,然后置于三维混合机中,于20r/min转速下混合30min;
S2,混匀的物料转入槽式混合机中,加入50%浓度食用乙醇溶液,混合均匀,制成软材;
S3,上述软材转入摇摆制粒机过30目筛网,制成初级颗粒;
S4,初级颗粒于50℃鼓风干燥4h,控制水分<5%;
S5,干燥后的初级颗粒分别过40目和60目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于20r/min转速下预混30min;
S7,再将配方量的硬脂酸镁投入三维混合机,于20r/min转速下预混20min;
S8,总混后的物料置于旋转式高速压片机中进行压片,片重控制在约0.65g/片。
对比例2:
一种养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖57份,葡萄籽提取物12份,蓝莓粉2份,甘草酸铵2份,微晶纤维素20份,表没食子儿茶素没食子酸酯1份,硬脂酸镁1份。
上述配方的制备方法,包括以下步骤:
S1,分别将葡萄籽提取物、蓝莓粉、甘草酸铵、表没食子儿茶素没食子酸酯过30目筛,并按照配方量混合,然后置于三维混合机中,于20r/min转速下混合30min;
S2,混匀的物料转入槽式混合机中,加入50%浓度食用乙醇溶液,混合均匀,制成软材;
S3,上述软材转入摇摆制粒机过30目筛网,制成初级颗粒;
S4,初级颗粒于50℃鼓风干燥4h,控制水分<5%;
S5,干燥后的初级颗粒分别过40目和60目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于20r/min转速下预混30min;
S7,再将配方量的硬脂酸镁投入三维混合机,于20r/min转速下预混20min;
S8,总混后的物料置于旋转式高速压片机中进行压片,片重控制在约0.65g/片。
对比例3:
一种养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖57份,葡萄籽提取物12份,蓝莓粉2份,枸杞粉2份,维生素C 3份,微晶纤维素20份,硬脂酸镁1份。
上述配方的制备方法,包括以下步骤:
S1,分别将葡萄籽提取物、蓝莓粉、枸杞粉、维生素C过30目筛,并按照配方量混合,然后置于三维混合机中,于20r/min转速下混合30min;
S2,混匀的物料转入槽式混合机中,加入50%浓度食用乙醇溶液,混合均匀,制成软材;
S3,上述软材转入摇摆制粒机过30目筛网,制成初级颗粒;
S4,初级颗粒于50℃鼓风干燥4h,控制水分<5%;
S5,干燥后的初级颗粒分别过40目和60目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于20r/min转速下预混30min;
S7,再将配方量的硬脂酸镁投入三维混合机,于20r/min转速下预混20min;
S8,总混后的物料置于旋转式高速压片机中进行压片,片重控制在约0.65g/片。
检测:
一、压片样品属性检测
1、试验方法
堆密度按照ASTMD 7481规定的方法进行测定;振实密度按照GB 5162规定的方法进行测定;卡尔系数=(振实密度-堆密度)/振实密度×100%;崩解性按照《中华人民共和国药典》(2015版四部通则)规定的方法进行测定;脆碎度按照《中华人民共和国药典》(2015版四部通则)规定的方法进行测定。
2、结果
表1数据显示,各实施例的总混物料及压片样品属性均优于对比例。其中,实施例2总混物料的卡尔系数小于实施例1和3,说明实施例1的总混物料流动性最佳。各实施例压片样品的脆碎度相差不大,均小于1%;崩解性最好的是实施例3,其次是实施例2。
表1总混物料及压片样品属性对比
注:卡尔系数评价标准:≤10%流动性非常好,11%~15%流动性好,16%~20%流动性尚可,21%~25%流动性一般,26%~31%流动性差,32%~37%流动性很差,≥38%流动性非常差。
3、结论
由试验结果可以看出,各实施例的总混物料及压片样品属性均优于对比例,并且实施例2的总混物料及压片样品属性明显优于实施例1和实施例3。
二、功效试验
1、原理
刀豆蛋白A(concanavalin A,ConA)是一种对肝细胞有特异性毒性作用的植物凝集素,它能在体外激活T细胞的丝裂原,进入循环后首先活化T淋巴细胞,继而激活肿瘤坏死因子(TNF)和白介素2(IL2)等细胞因子,引发炎症反应,可诱导淋巴细胞、巨噬细胞的细胞毒作用,诱导肝细胞凋亡等多种途径损伤肝细胞。
2、试验材料
2.1试验动物:成年小鼠120只,单一性别,体重18~22g/只,平均分成8组,各组5只,分别为阴性对照组、模型组、实施例1样品组、实施例2样品组、实施例3样品组、对比例1样品组、对比例2样品组、对比例3样品组。
2.2试验样品:超纯水、实施例1~3制备的样品、对比例1~3制备的样品。
3、试验方法
3.1试样超声波溶于超纯水,制成浓度为0.1g/mL的悬液,作为受试样品。试验组经口灌胃给予实施例或对比例制备的受试样品5mL/d,空白对照组和模型组给予超纯水,连续给予30d。将动物每周称重两次,以调整受试样品剂量。
3.2模型组及各试验组于实验结束时,一次性尾静脉注射刀豆蛋白A,剂量为10mL/(kg BW),禁食8h后经腹腔注射剂量为60mg/(kg BW)的戊巴比妥钠溶液麻醉,腹主动脉采血,并取肝组织,进行各项指标的检测及病理组织学检查。
3.3检测指标:血清中谷丙转氨酶(ALT)、血清中谷草转氨酶(AST)、血清中乳酸脱氢酶(LDH)含量、肝脏病理组织学检查。
3.4数据处理
数据采用方差分析,但需按方差分析的程序先进行方差齐性检验。方差齐,计算F值,F值<F0.05,各组均数间差异无显著性;F值>F0.05,用多个实验组和一个对照组间均数的两两比较方法进行统计。对非正态或方差不齐的数据进行适当的变量转换,待满足正态或方差齐要求后,用转换后的数据进行统计;若变量转换后仍未达到正态或方差齐的目的,改用秩和检验进行统计。
3.5结果判定
3.5.1模型对照组与阴性对照组比较,血清ALT、AST和LDH含量升高有统计学意义(p<0.05),表示模型成立。在模型成立的前提下,受试样品组血清ALT、AST和LDH含量与模型对照组比较降低,差异有显著性(p<0.05),可分别判定ALT、AST和LDH指标结果阳性。
3.5.2肝细胞损伤评分标准
表2肝细胞损伤评分标准
项目 | 分值 |
大致正常 | 0分 |
偶见坏死细胞 | 1分 |
坏死细胞小于整个视野的1/4 | 2分 |
坏死细胞占整个视野的1/4~1/2 | 3分 |
坏死细胞占整个视野的1/2~3/4 | 4分 |
坏死细胞弥漫整个视野 | 5分 |
4、试验结果
4.1小鼠肝脂肪酶(HL)、血清AST(谷草转氨酶)、ALT(谷丙转氨酶)和LDH(乳酸脱氢酶)测定结果,如图1至图4所示所示。
HL是体内脂质代谢的三大关键酶之一对控制体内TG、TCH含量,维持HDL的正常水平起重要作用;血清ALT、AST和LDH也是衡量肝功的重要指标。如图1至图4所示,试验组的HL指数均均高于模型组,而略低于阴性对照组,并且对比例各组明显低于实施例组;其中D组HL指数高于C组,并与E组基本持平。同时图1至图4显示,对于血清AST、ALT和LDH,试验组均低于模型组,并且实施例各组明显低于对比例;其中C组明显高于D组,而E组略高于D组或与之持平。
以上数据说明,本发明实施例和对比例在维持肝功方面都有促进作用。其中实施例效果明显优于对比例,并且综合来看实施例2对应的样品效果最佳。具体地,对比例1中未添加葡萄籽提取物和蓝莓粉,而葡萄籽和蓝莓含有丰富的低聚原花青素和蓝莓花青素,能清除ROS,提高SDO活性,降低脂质过氧化反应,清除自由基,保护肝脏组织受到自由基氧化损伤。对比例2未添加枸杞粉和维生素C,而枸杞粉和维生素C对于维持还原态环境,降低并修复细胞内质网损伤,促进细胞蛋白合成及解毒功能,恢复肝实质细胞功能,并促进其再生的作用。对比例3未添加甘草酸铵和表没食子儿茶素没食子酸酯,而甘草酸铵和表没食子儿茶素没食子酸酯可降低ALT和AST释放量,改善受损肝细胞活率,促进转氨酶代谢,抑制由脂肪浸润导致的炎症反应、以及抗病毒作用。从实验数据的结果来看,对比例中的数据显示肝脏指标均明显低于实施例,从而使得对比例1、对比例2和对比例3在维持肝功方面并没本发明中实施例1、实施例2和实施例3的效果好。
4.2肝细胞损伤病理结果判定
表3肝细胞损伤评分比较
组别 | 肝细胞损伤评分 |
阴性对照组 | 0 |
模型组 | 4.5 |
实施例1 | 1.1 |
实施例2 | 0.3 |
实施例3 | 0..5 |
对比例1 | 2.6 |
对比例2 | 2.5 |
对比例3 | 2.7 |
注:肝细胞损伤评分值分别为各组的平均值
表3数据显示,模型组与阴性对照组比较肝细胞损伤程度加重有统计学意义(p<0.05),表示模型成立。在模型成立的前提下,实施例1~3样品组与模型组比较,肝细胞的损伤程度均有明显减轻,均有统计学意义(p<0.05),其中实施例2样品组得分最低;对比例1~3样品组与模型组比较,肝细胞的损伤程度也均有明显减轻,均有统计学意义(p<0.05),其中对比例2样品组得分最低。与对比例2样品组相比较,实施例2样品组肝细胞损伤评分更低,具有统计学意义(p>0.05)。
以上统计学比较说明,实施例1~3样品组、对比例1~3样品组均具有减轻肝细胞坏死程度的功效,但是实施例明显优于对比例,其中实施例2功效最佳。
5、结论
综上所述,本发明提供的一种养护肝脏的食疗养生的压片糖果,对肝损伤有修复功能,有助于肝脏的养护。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明前提下,还可以作出一些相应的改进及拓展应用,这些改进和拓展应用也应该视为发明的保护范围。
Claims (9)
1.一种养护肝脏的压片糖果,其特征在于,包括如下重量份数的物质:海藻糖20~90份,葡萄籽提取物1~40份,蓝莓粉1~8份,枸杞粉1~8份,维生素C 1~10份,甘草酸铵1~8份,微晶纤维素1~50份,表没食子儿茶素没食子酸酯0.1~5份,硬脂酸镁0.1~5份。
2.根据权利要求1所述的养护肝脏的压片糖果,其特征在于,包括如下重量份数的物质:海藻糖40~80份,葡萄籽提取物5~30份,蓝莓粉3~5份,枸杞粉3~5份,维生素C 2~6份,甘草酸铵3~5份,微晶纤维素10~30份,表没食子儿茶素没食子酸酯0.5~2份,硬脂酸镁0.5~2份。
3.根据权利要求1所述的养护肝脏的压片糖果,其特征在于,包括如下重量份数的物质:海藻糖40份,葡萄籽提取物5份,蓝莓粉1份,枸杞粉1份,维生素C 2份,甘草酸铵1份,微晶纤维素2份,表没食子儿茶素没食子酸酯0.1份,硬脂酸镁0.1份。
4.根据权利要求1或2所述的养护肝脏的压片糖果,其特征在于,包括如下重量份数的物质:海藻糖57份,葡萄籽提取物12份,蓝莓粉2份,枸杞粉2份,维生素C 3份,甘草酸铵2份,微晶纤维素20份,表没食子儿茶素没食子酸酯1份,硬脂酸镁1份。
5.根据权利要求1所述的养护肝脏的压片糖果,包括如下重量份数的物质:海藻糖80份,葡萄籽提取物25份,蓝莓粉5份,枸杞粉5份,维生素C 6份,甘草酸铵5份,微晶纤维素30份,表没食子儿茶素没食子酸酯2份,硬脂酸镁2份。
6.根据权利要求1至5中任一权利要求所述的养护肝脏的压片糖果的制备方法,包括以下步骤:
S1,分别按照比例将葡萄籽提取物、蓝莓粉、枸杞粉、维生素C、甘草酸铵和表没食子儿茶素没食子酸酯过30目筛,并按照配方量混合,然后置于三维混合机中,于10~30r/min转速下混合20~40min;
S2,混匀的物料转入槽式混合机中,加入40%~60%的食用乙醇溶液,混合均匀,制成软材;
S3,将软材转入摇摆制粒机过20~40目筛网,制成初级颗粒;
S4,将初级颗粒鼓风干燥,控制水分<5%;
S5,干燥后的初级颗粒分别过30~50目和50~70目筛网进行整粒;
S6,分别将海藻糖、微晶纤维素过30目筛,然后按配方量与制粒后的预混料混合,投入三维混合机中,于10~30r/min转速下预混20~40min;
S7,再将配方量的硬脂酸镁投入三维混合机,于10~30r/min转速下总混10~30min;
S8,总混后的物料置于旋转式高速压片机中进行压片。
7.根据权利要求6中任一权利要求所述的养护肝脏的压片糖果的制作方法,其特征在于:S4中初级颗粒于40~60℃鼓风干燥3~6h。
8.根据权利要求6中任一权利要求所述的养护肝脏的压片糖果的制作方法,其特征在于:S8中片重为0.6~0.8g/片。
9.根据权利要求1至8中任一权利要求所述的养护肝脏的压片糖果的应用,其特征在于:直接食用来养护肝脏。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910276758.0A CN109965072A (zh) | 2019-04-08 | 2019-04-08 | 一种养护肝脏的压片糖果及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910276758.0A CN109965072A (zh) | 2019-04-08 | 2019-04-08 | 一种养护肝脏的压片糖果及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109965072A true CN109965072A (zh) | 2019-07-05 |
Family
ID=67083329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910276758.0A Pending CN109965072A (zh) | 2019-04-08 | 2019-04-08 | 一种养护肝脏的压片糖果及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109965072A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110607339A (zh) * | 2019-09-24 | 2019-12-24 | 花姐生物科技(杭州)有限公司 | 一种基于人肝实质细胞用于功能性食品功效检测的方法 |
CN112869073A (zh) * | 2021-03-05 | 2021-06-01 | 郭宝叶 | 提高人体机能和排出有害毒素的中药果蔬组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104172159A (zh) * | 2014-07-24 | 2014-12-03 | 北京中泰天和科技有限公司 | 一种对酒精性肝损伤具有辅助保护作用的组合物及其制备方法 |
CN104783031A (zh) * | 2015-04-02 | 2015-07-22 | 国药集团健康产业研究院有限公司 | 一种护肝护脑组合物 |
CN106509305A (zh) * | 2016-10-31 | 2017-03-22 | 江西熙帝生物科技有限公司 | 一种具有护肝功能的压片糖 |
CN107912591A (zh) * | 2017-11-29 | 2018-04-17 | 威海养经堂医药科技有限公司 | 一种蓝莓精片压片糖果 |
CN108576819A (zh) * | 2018-04-24 | 2018-09-28 | 北京中和鸿业医药科技有限公司 | 一种护肝组合物、保健食品、制备方法及其应用 |
CN108926595A (zh) * | 2018-07-27 | 2018-12-04 | 步源堂生物科技有限公司 | 一种具有保护肝脏和降血脂功能的保健品 |
-
2019
- 2019-04-08 CN CN201910276758.0A patent/CN109965072A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104172159A (zh) * | 2014-07-24 | 2014-12-03 | 北京中泰天和科技有限公司 | 一种对酒精性肝损伤具有辅助保护作用的组合物及其制备方法 |
CN104783031A (zh) * | 2015-04-02 | 2015-07-22 | 国药集团健康产业研究院有限公司 | 一种护肝护脑组合物 |
CN106509305A (zh) * | 2016-10-31 | 2017-03-22 | 江西熙帝生物科技有限公司 | 一种具有护肝功能的压片糖 |
CN107912591A (zh) * | 2017-11-29 | 2018-04-17 | 威海养经堂医药科技有限公司 | 一种蓝莓精片压片糖果 |
CN108576819A (zh) * | 2018-04-24 | 2018-09-28 | 北京中和鸿业医药科技有限公司 | 一种护肝组合物、保健食品、制备方法及其应用 |
CN108926595A (zh) * | 2018-07-27 | 2018-12-04 | 步源堂生物科技有限公司 | 一种具有保护肝脏和降血脂功能的保健品 |
Non-Patent Citations (1)
Title |
---|
邹海民等: "《市售保健品中7种醒酒护肝功效成分的毛细管电泳测定》", 《高等学校化学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110607339A (zh) * | 2019-09-24 | 2019-12-24 | 花姐生物科技(杭州)有限公司 | 一种基于人肝实质细胞用于功能性食品功效检测的方法 |
CN112869073A (zh) * | 2021-03-05 | 2021-06-01 | 郭宝叶 | 提高人体机能和排出有害毒素的中药果蔬组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180200284A1 (en) | Multi-functional Composition and Preparation Method and Application Thereof | |
CN104322617B (zh) | 一种辅助降血糖的饼干及其制备方法 | |
CN104013698A (zh) | 一种具有辅助降血脂功能的纳豆山楂胶囊及其制备方法 | |
CN109549097A (zh) | 一种具有降糖降脂功能的保健面条 | |
CN103976110A (zh) | 一种雪菊茶珍及其制备方法 | |
CN109965072A (zh) | 一种养护肝脏的压片糖果及其制备方法与应用 | |
CN109123351A (zh) | 一种具有高血糖人群代餐调节功能的特医食品及制备方法 | |
CN104388236A (zh) | 一种葡萄酒及其制备方法与应用 | |
CN105943958A (zh) | 一种治疗痛风的桦褐孔菌复合固体颗粒及其制备方法 | |
CN103609964B (zh) | 保健粗粮挂面及其制备工艺 | |
CN117814341A (zh) | 一种用于体重管理的压片糖果及其制备方法 | |
CN107136281A (zh) | 一种用于改善女性肾功能的昆布虫草压片糖果及其制备方法 | |
CN103920140B (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN116268107A (zh) | 具有抗抑郁功能的配方羊乳粉及其制备方法 | |
CN110384240A (zh) | 降血糖的维生素和益生菌发酵物粉营养组合物及其应用 | |
CN105031419A (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
CN114342979A (zh) | 一种满足垂钓需求的压缩饼干及其制备方法 | |
JP2001269135A (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
CN107397091A (zh) | 一种抗疲劳的苣荬菜运动饮料 | |
CN105995980A (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
CN106177227A (zh) | 一种增强人体免疫力的含辅酶q10的组合物 | |
CN108991358A (zh) | 一种辅助降血脂、降血糖、缓解痛风保健食品及生产方法 | |
CN101530209A (zh) | 一种调节血脂及护肝的保健食品及其制备方法 | |
CN110302340A (zh) | 一种具有降血脂功能的中药片剂及其制备方法 | |
CN111838653A (zh) | 一种蓝莓葡萄籽维a软胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |
|
RJ01 | Rejection of invention patent application after publication |